Characteristics of participants and recurrent VTE during follow-up
| Source . | All participants . | APLA positive . | APLA negative . | |||||
|---|---|---|---|---|---|---|---|---|
| N . | % Female . | Age mean . | Type VTE* (%) . | Risk factors† (%) . | APLA type (N) . | Recurrent VTE n/N . | Recurrent VTE (n/N) . | |
| Bank, 2003 | 64 | 56 | 54 | DVT: 100 | NR cancer: 3% | ACLA only 5 | ACLA 0/5 | 0/57 |
| Proximal: 100 | LA only 2 | LA 0/2 | ||||||
| Distal: 0 | ||||||||
| PE: 0 | ||||||||
| Ginsberg, 1995 | 65 | 55 | NR | DVT: 66 | NR | ACLA only 7 | ACLA only 0/7 | 1/49 on |
| PE: 34 | LA only 7 | LA only 2/7 | 6/34 off | |||||
| Both 2 | Both only 0/2 | |||||||
| 0/16 on | ||||||||
| 2/11 off | ||||||||
| Kearon, 1999 | 77 | 47 | 58 | DVT: 73 | Unprovoked: 100% | ACLA only 3 | ACLA 2/3 | 12/71 |
| PE: 27 | LA only 3 | LA 2/3 | ||||||
| Kearon, 2004 | 141 | 47 | 56 | DVT: 77 | Temporary RF: 100% | ACLA only 10 | ACLA only 0/10 | 6/124 |
| Proximal: 53 | LA only 6 | LA 1/6 | ||||||
| Distal: 24 | Both 1 | Both 0/1 | ||||||
| PE: 22 | ||||||||
| Rodger, 2008 | 619 | 49 | 53 | DVT: 52 (all proximal) | Unprovoked: 100% | NRNS | 56/384 | 31/235 |
| PE: 30 | ||||||||
| PE + DVT: 17 | ||||||||
| Wahlander, 2005 (ximelagatran) | 528 | 46 | 56 | DVT: 66 | NR cancer: 6% | All ACLA | 2/45 | 5/483 |
| Proximal: 46 | ||||||||
| Distal: 20 | ||||||||
| PE: 17 | ||||||||
| PE + DVT: 16 | ||||||||
| Wahlander, 2005 (placebo) | 513 | 49‡ | 58‡ | DVT: 64‡ | NR cancer: 5% | All ACLA | 5/48 | 49/465 |
| Proximal: 44‡ | ||||||||
| Distal: 20‡ | ||||||||
| PE: 15‡ | ||||||||
| PE + DVT: 21‡ | ||||||||
| Taliani, 2009 | 297 | 45 | 64 | NR (proximal DVT or PE) | Unprovoked: 100% | NR | 3/6 | 76/291 |
| Schulman, 2006 | ∼810 | 45§ | 61§ | DVT: 88%§ | Unprovoked: 62% | All ACLA | 38/116 | 194/694 |
| Proximal: 49%§ | Temporary RF: 38% | |||||||
| Distal: 39%§ | ||||||||
| PE: 12%§ | ||||||||
| Source . | All participants . | APLA positive . | APLA negative . | |||||
|---|---|---|---|---|---|---|---|---|
| N . | % Female . | Age mean . | Type VTE* (%) . | Risk factors† (%) . | APLA type (N) . | Recurrent VTE n/N . | Recurrent VTE (n/N) . | |
| Bank, 2003 | 64 | 56 | 54 | DVT: 100 | NR cancer: 3% | ACLA only 5 | ACLA 0/5 | 0/57 |
| Proximal: 100 | LA only 2 | LA 0/2 | ||||||
| Distal: 0 | ||||||||
| PE: 0 | ||||||||
| Ginsberg, 1995 | 65 | 55 | NR | DVT: 66 | NR | ACLA only 7 | ACLA only 0/7 | 1/49 on |
| PE: 34 | LA only 7 | LA only 2/7 | 6/34 off | |||||
| Both 2 | Both only 0/2 | |||||||
| 0/16 on | ||||||||
| 2/11 off | ||||||||
| Kearon, 1999 | 77 | 47 | 58 | DVT: 73 | Unprovoked: 100% | ACLA only 3 | ACLA 2/3 | 12/71 |
| PE: 27 | LA only 3 | LA 2/3 | ||||||
| Kearon, 2004 | 141 | 47 | 56 | DVT: 77 | Temporary RF: 100% | ACLA only 10 | ACLA only 0/10 | 6/124 |
| Proximal: 53 | LA only 6 | LA 1/6 | ||||||
| Distal: 24 | Both 1 | Both 0/1 | ||||||
| PE: 22 | ||||||||
| Rodger, 2008 | 619 | 49 | 53 | DVT: 52 (all proximal) | Unprovoked: 100% | NRNS | 56/384 | 31/235 |
| PE: 30 | ||||||||
| PE + DVT: 17 | ||||||||
| Wahlander, 2005 (ximelagatran) | 528 | 46 | 56 | DVT: 66 | NR cancer: 6% | All ACLA | 2/45 | 5/483 |
| Proximal: 46 | ||||||||
| Distal: 20 | ||||||||
| PE: 17 | ||||||||
| PE + DVT: 16 | ||||||||
| Wahlander, 2005 (placebo) | 513 | 49‡ | 58‡ | DVT: 64‡ | NR cancer: 5% | All ACLA | 5/48 | 49/465 |
| Proximal: 44‡ | ||||||||
| Distal: 20‡ | ||||||||
| PE: 15‡ | ||||||||
| PE + DVT: 21‡ | ||||||||
| Taliani, 2009 | 297 | 45 | 64 | NR (proximal DVT or PE) | Unprovoked: 100% | NR | 3/6 | 76/291 |
| Schulman, 2006 | ∼810 | 45§ | 61§ | DVT: 88%§ | Unprovoked: 62% | All ACLA | 38/116 | 194/694 |
| Proximal: 49%§ | Temporary RF: 38% | |||||||
| Distal: 39%§ | ||||||||
| PE: 12%§ | ||||||||
All VTE were symptomatic except for 9% of patients in 1 study17 who had asymptomatic DVT detected by postoperative screening tests.
When described, the proportion of patients with cancer, VTE provoked by a temporary risk factor or unprovoked VTE is presented.
Data obtained from an earlier report (ref: Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J of Med. 1995;332:1661-1665.); all patients in that report were not included in the APLA analysis.
Data obtained from an earlier report (ref: Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med. 1998;104(4):332-338.); all patients in that report were not included in the APLA analysis.
NR, not reported; temporary RF, provoked by a temporary risk factor.